Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

114 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Industria
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Convalidate in UE due domande di autorizzazione per terapie ipolipemizzanti a tripla combinazione con una sola compressa
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
29/10/2026
Industria
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
27/10/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
02/10/2026
Mercato del lavoro
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
25/09/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
18/09/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
14/09/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
01/09/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
28/08/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Nuovi dati di Daiichi Sankyo evidenziano l'effetto dell'acido bempedoico nella gestione della dislipidemia e del rischio cardiovascolare nella pratica clinica
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0